EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm

Elena Crisà iD, Irene Dogliotti, Giuseppe Lia, Marco Cerrano, Ernesta Audisio, Giuseppe Lanzarone iD, Lucia Brunello, Daniela Caravelli, Fabrizio Carnevale Schianca, Enrico Berrino iD, Sara Erika Bellomo, Alice Bartolini und 6 weitere

Cancers · 01.09.2025 · 17 (17) · 2874

DOI: 10.3390/cancers17172874 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 01.09.2025. Verfasst von Elena Crisà und 17 weiteren Autor:innen. Beteiligte Einrichtung: Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FPRC 5x1000 Ministero della Salute, 2021 EMAGEN, Italian Ministry of Health, Ricerca Corrente 2025.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives. Recent evidence underscores the prognostic and classificatory relevance of somatic mutations in myelodysplastic neoplasms (MDSs) and acute myeloid leukemia (AML).

Methods

This prospective study assessed gene mutation dynamics via next-generation sequencing (NGS) in 84 MDS/AML patients treated with intensive chemotherapy or hypomethylating agents plus venetoclax.

Results

At diagnosis, 95% had somatic mutations detected by NGS, while only 29% had a measurable residual disease (MRD) marker with qPCRs. NGS at complete remission (CR) was performed in 56/71 patients who achieved CR; 59% had persisting mutations, mostly in DNMT3A, TET2, and ASXL1 (DTA mutations). Mutations’ persistence in CR was linked to a shorter relapse-free survival (RFS; median 8 months vs. not reached, HR 4.41, 95% CI 1.69–11.49; p = 0.002) and overall survival (OS; 2-year OS: 51.5% vs. 88%, HR 4.02, 95% CI 1.39–11.65; p = 0.001). Combining NGS and multiparameter flow cytometry (MFC) for MRD detection, we divided patients into three groups with distinct RFS (NGS−/MFC−, NGS−/MFC+, or NGS+/MFC− and NGS+/MFC+), with double-negative patients displaying the best RFS (p < 0.001). In the multivariate analysis, NGS and MFC MRD+ were independent predictors of RFS.

Conclusions

This real-world study confirms the added prognostic role of NGS in MRD detection on RFS, particularly when combined with MFC. This approach may improve risk stratification and guide treatment decisions.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemiaallogeneic stem cell transplantationminimal residual diseasemyelodysplastic syndromesnext generation sequencing

Autor:innen und Institutionen

  • Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
  • Division of Hematology U, University Hospital A.O.U. "Città della Salute e della Scienza", University of Turin, 10126 Torino, Italy.
  • Department of Molecular Biotechnologies and Health Sciences, University of Torino, 10126 Torino, Italy.
  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
  • SCDU Ematologia, AOU SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy.
  • Department of Medical Sciences, University of Torino, 10100 Torino, Italy.

ORCID-Profile: Elena Crisà, Giuseppe Lanzarone, Enrico Berrino, Gianluca Gaidano, Luisa Giaccone, Benedetto Bruno

Förderung

  • FPRC 5x1000 Ministero della Salute
  • 2021 EMAGEN
  • Italian Ministry of Health, Ricerca Corrente 2025
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • FPRC 5 × 1000 Ministero della Salute 2021 EMAGEN—FaBer
  • Janssen Pharmaceutical Companies of Johnson &amp; Johnson

Zitieren

APA

Crisà, E., Dogliotti, I., Lia, G., Cerrano, M., Audisio, E., Lanzarone, G., Brunello, L., Caravelli, D., Carnevale Schianca, F., Berrino, E., Bellomo, S. E., Bartolini, A., Riera, L., Francia di Celle, P., Gaidano, G., Lunghi, M., Giaccone, L., & Bruno, B. (2025). Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm. Cancers, 17(17), 2874. https://doi.org/10.3390/cancers17172874

Vancouver

Crisà E, Dogliotti I, Lia G, Cerrano M, Audisio E, Lanzarone G, et al. Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm. Cancers. 2025;17(17):2874. doi:10.3390/cancers17172874

BibTeX
@article{Cris2025,
  author = {Crisà, Elena and Dogliotti, Irene and Lia, Giuseppe and Cerrano, Marco and Audisio, Ernesta and Lanzarone, Giuseppe and Brunello, Lucia and Caravelli, Daniela and Carnevale Schianca, Fabrizio and Berrino, Enrico and Bellomo, Sara Erika and Bartolini, Alice and Riera, Ludovica and Francia di Celle, Paola and Gaidano, Gianluca and Lunghi, Monia and Giaccone, Luisa and Bruno, Benedetto},
  title = {Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {17},
  pages = {2874},
  doi = {10.3390/cancers17172874}
}
Kostenlos starten →